Lilly Cancer Drug Gets Hesitant Support from FDA Panel

Source: Reuters

Jul 10, 2015

In an informal poll, an FDA advisory panel effectively supported approval of Eli Lilly & Co's experimental lung cancer drug, necitumumab.

In a 1,093-patient clinical trial, necitumumab improved overall survival by an average of 1.6 months but also increased the risk of blood clots and electrolyte imbalances, both dangerous and potentially fatal side-effects.

While the survival benefits of the drug are modest at best, the drug makes headway with a disease -- advanced squamous NSCLC -- that only has a five-year survival rate of less than 5 percent.

Read the Reuters article

Return to the Web Watcher Newsletter